Sign in Subscribe
Class action lawsuits

Altimmune, Inc. Faces Class Action Lawsuit Over Securities Fraud Allegations

Strategic Insights

— 1 min read

Altimmune, Inc.'s securities fraud allegations have sparked a class action lawsuit, seeking to recover losses for shareholders affected by the company's supposed misleading statements. The lawsuit claims that Altimmune intentionally deceived investors by showcasing inflated expectations for its Pemvidutide treatment in the IMPACT Phase 2b MASH trial. This led to a significant decline in the company's stock price, with shares falling from $7.71 to $3.61 in just one day, a drop of 53.2%.

Key Takeaways:

  • A class action lawsuit was filed against Altimmune, Inc. for alleged securities fraud between August 10, 2023, and June 25, 2025, impacting shareholders who suffered losses.
  • The lawsuit centers around the company's press release on June 26, 2025, announcing topline results from the IMPACT Phase 2b MASH trial of Pemvidutide, which failed to meet statistical significance in its analysis of the fibrosis reduction primary endpoint.
  • Altimmune's response to the concerning miss was attributed to the trial's Phase 2 nature, stating the company was hoping for better results following the Phase 3 trial.
  • Following the announcement, the price of Altimmune's common stock plummeted, with shares experiencing a 53.2% decline in one day.
  • Levi & Korsinsky, LLP, a national securities litigation firm, is representing the plaintiff in this case, citing their expertise in complex securities litigation and extensive track record of winning high-stakes cases.
  • The firm has secured hundreds of millions of dollars for aggrieved shareholders and has been ranked in ISS Securities Class Action Services' Top 50 Report as one of the top securities litigation firms in the United States for seven consecutive years.

Statistics:

  • Stock price: $7.71 (one day before the announcement) to $3.61 (the day following the announcement), a decline of 53.2%
  • Date range for alleged securities fraud: August 10, 2023, and June 25, 2025
  • Number of employees at Levi & Korsinsky, LLP: 70+
  • Years of experience in representing investors in complex securities litigation: 20+

Sources:

  • Newsfile Corp. - August 18, 2025
  • https://www.newsfilecorp.com/release/262971 (original press release)
  • https://zlk.com/pslra-1/altimmune-inc-lawsuit-submission-form-2?prid=162169&wire=5&utm_campaign=26 (submission form)
  • (212) 363-7500 (Levi & Korsinsky, LLP phone number)
  • jlevi@levikorsinsky.com (Joseph E. Levi, Esq. email address)

Read more